Synairgen plc (SYGGF)
USD 0.04
(-23.64%)
USD 0.04
(-23.64%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -10.51 Million GBP | 33.97% |
| 2022 | -15.92 Million GBP | 52.92% |
| 2021 | -33.82 Million GBP | 54.81% |
| 2020 | -74.84 Million GBP | -3420.6% |
| 2019 | -2.12 Million GBP | 59.77% |
| 2018 | -5.28 Million GBP | -9.06% |
| 2017 | -4.84 Million GBP | -56.09% |
| 2016 | -3.1 Million GBP | 22.24% |
| 2015 | -3.99 Million GBP | -40.22% |
| 2014 | -2.84 Million GBP | -241.37% |
| 2013 | -834 Thousand GBP | 49.64% |
| 2012 | -1.65 Million GBP | -10.99% |
| 2011 | -1.49 Million GBP | -12.01% |
| 2010 | -1.33 Million GBP | 77.64% |
| 2009 | -5.95 Million GBP | -983.27% |
| 2008 | -550 Thousand GBP | 45.54% |
| 2007 | -1.01 Million GBP | -4950.0% |
| 2006 | -20 Thousand GBP | 74.36% |
| 2005 | -78 Thousand GBP | -36.84% |
| 2004 | -57 Thousand GBP | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 Q4 | -10.51 Million GBP | 0.0% |
| 2023 Q1 | -10.63 Million GBP | 33.25% |
| 2023 FY | -10.51 Million GBP | 33.97% |
| 2023 Q3 | -10.51 Million GBP | 1.08% |
| 2023 Q2 | -10.63 Million GBP | 0.0% |
| 2022 Q3 | -15.92 Million GBP | 11.63% |
| 2022 Q2 | -18.02 Million GBP | 0.0% |
| 2022 FY | -15.92 Million GBP | 52.92% |
| 2022 Q1 | -18.02 Million GBP | 46.72% |
| 2022 Q4 | -15.92 Million GBP | 0.0% |
| 2021 Q3 | -33.82 Million GBP | 26.73% |
| 2021 Q2 | -46.16 Million GBP | 0.1% |
| 2021 FY | -33.82 Million GBP | 54.81% |
| 2021 Q1 | -46.21 Million GBP | 38.26% |
| 2021 Q4 | -33.82 Million GBP | 0.0% |
| 2020 FY | -74.84 Million GBP | -3420.6% |
| 2020 Q1 | -10.84 Million GBP | -409.92% |
| 2020 Q2 | -10.67 Million GBP | 1.52% |
| 2020 Q4 | -74.84 Million GBP | 0.17% |
| 2020 Q3 | -74.97 Million GBP | -602.29% |
| 2019 Q1 | -3.52 Million GBP | 33.38% |
| 2019 Q3 | -2.32 Million GBP | 33.89% |
| 2019 Q4 | -2.12 Million GBP | 8.64% |
| 2019 FY | -2.12 Million GBP | 59.77% |
| 2019 Q2 | -3.52 Million GBP | 0.0% |
| 2018 Q1 | -4.05 Million GBP | 16.28% |
| 2018 FY | -5.28 Million GBP | -9.06% |
| 2018 Q4 | -5.28 Million GBP | 0.0% |
| 2018 Q3 | -5.28 Million GBP | -30.28% |
| 2018 Q2 | -4.05 Million GBP | 0.0% |
| 2017 Q1 | -2.81 Million GBP | 9.25% |
| 2017 Q4 | -4.84 Million GBP | 0.0% |
| 2017 FY | -4.84 Million GBP | -56.09% |
| 2017 Q3 | -4.84 Million GBP | -71.99% |
| 2017 Q2 | -2.81 Million GBP | 0.0% |
| 2016 Q1 | -3.81 Million GBP | 4.53% |
| 2016 FY | -3.1 Million GBP | 22.24% |
| 2016 Q4 | -3.1 Million GBP | 0.0% |
| 2016 Q3 | -3.1 Million GBP | 18.55% |
| 2016 Q2 | -3.81 Million GBP | 0.0% |
| 2015 Q4 | -3.99 Million GBP | 0.0% |
| 2015 Q2 | -4.01 Million GBP | 0.0% |
| 2015 Q1 | -4.01 Million GBP | -41.13% |
| 2015 Q3 | -3.99 Million GBP | 0.65% |
| 2015 FY | -3.99 Million GBP | -40.22% |
| 2014 Q3 | -2.84 Million GBP | 43.93% |
| 2014 Q4 | -2.84 Million GBP | 0.0% |
| 2014 Q2 | -5.07 Million GBP | 0.0% |
| 2014 Q1 | -5.07 Million GBP | -508.87% |
| 2014 FY | -2.84 Million GBP | -241.37% |
| 2013 Q4 | -834 Thousand GBP | 0.0% |
| 2013 Q2 | -1.27 Million GBP | 0.0% |
| 2013 FY | -834 Thousand GBP | 49.64% |
| 2013 Q1 | -1.27 Million GBP | 22.77% |
| 2013 Q3 | -834 Thousand GBP | 34.79% |
| 2012 Q4 | -1.65 Million GBP | 0.0% |
| 2012 Q2 | -875 Thousand GBP | 0.0% |
| 2012 FY | -1.65 Million GBP | -10.99% |
| 2011 FY | -1.49 Million GBP | -12.01% |
| 2011 Q2 | -1.49 Million GBP | 0.0% |
| 2010 Q2 | -1.33 Million GBP | 0.0% |
| 2010 Q4 | -1.17 Million GBP | 0.0% |
| 2010 FY | -1.33 Million GBP | 77.64% |
| 2009 Q2 | -5.95 Million GBP | 0.0% |
| 2009 Q4 | -700 Thousand GBP | 0.0% |
| 2009 FY | -5.95 Million GBP | -983.27% |
| 2008 Q4 | -580 Thousand GBP | 0.0% |
| 2008 Q2 | -550 Thousand GBP | 0.0% |
| 2008 FY | -550 Thousand GBP | 45.54% |
| 2007 Q2 | -1.01 Million GBP | 0.0% |
| 2007 Q4 | -766 Thousand GBP | 0.0% |
| 2007 FY | -1.01 Million GBP | -4950.0% |
| 2006 Q4 | -515 Thousand GBP | 0.0% |
| 2006 FY | -20 Thousand GBP | 74.36% |
| 2006 Q2 | -20 Thousand GBP | 0.0% |
| 2005 Q4 | -80 Thousand GBP | 0.0% |
| 2005 FY | -78 Thousand GBP | -36.84% |
| 2005 Q2 | -78 Thousand GBP | 0.0% |
| 2004 Q2 | -407 Thousand GBP | 0.0% |
| 2004 Q4 | -48 Thousand GBP | 0.0% |
| 2004 FY | -57 Thousand GBP | 0.0% |
| 2003 Q4 | -36 Thousand GBP | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 15.76 Million USD | 166.713% |
| Nanobac Pharmaceuticals, Incorporated | 4.11 Million USD | 355.365% |
| SQZ Biotechnologies Company | -36.23 Million USD | 70.981% |
| Evofem Biosciences, Inc. | 42.79 Million USD | 124.574% |
| Santhera Pharmaceuticals Holding AG | -6.3 Million USD | -66.801% |
| Mesoblast Limited | 55.85 Million USD | 118.826% |
| Propanc Biopharma, Inc. | 927.18 Thousand USD | 1234.185% |
| Genus plc | 190.6 Million USD | 105.517% |
| VioQuest Pharmaceuticals, Inc. | 2.23 Million USD | 570.339% |
| CNBX Pharmaceuticals Inc. | 1.21 Million USD | 966.307% |
| Marizyme, Inc. | 18.56 Million USD | 156.632% |
| ContraFect Corporation | -6.02 Million USD | -74.51% |
| Nymox Pharmaceutical Corporation | 680 Thousand USD | 1646.471% |
| PsyBio Therapeutics Corp. | 134.63 Thousand USD | 7910.516% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.15 Million USD | 1010.138% |
| Intellipharmaceutics International Inc. | 2.24 Million USD | 568.997% |
| AXIM Biotechnologies, Inc. | 5.5 Million USD | 291.134% |
| MultiCell Technologies, Inc. | 90.04 USD | 11679353.665% |
| Accustem Sciences Inc. | -733.97 Thousand USD | -1332.74% |
| RVL Pharmaceuticals plc | 12.94 Million USD | 181.23% |
| EV Biologics, Inc. | 1.36 Million USD | 868.73% |
| Q BioMed Inc. | 4.06 Million USD | 359.014% |
| Emmaus Life Sciences, Inc. | 30.55 Million USD | 134.418% |
| Neon Bloom, Inc. | 622.36 Thousand USD | 1789.686% |
| Mosaic ImmunoEngineering Inc. | 1 Million USD | 1143.548% |
| Biomind Labs Inc. | 711.4 Thousand USD | 1578.208% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Pharming Group N.V. | 109.8 Million USD | 109.577% |
| Oncotelic Therapeutics, Inc. | 12.8 Million USD | 182.114% |
| Skye Bioscience, Inc. | -5.72 Million USD | -83.802% |
| Therapeutic Solutions International, Inc. | 860.24 Thousand USD | 1322.448% |
| THC Farmaceuticals, Inc. | 139.8 Thousand USD | 7621.959% |
| Arch Therapeutics, Inc. | 5.64 Million USD | 286.178% |
| IMV Inc. | 7.67 Million USD | 237.096% |
| Acro Biomedical Co., Ltd. | 19.86 Thousand USD | 53031.998% |
| Curative Biotechnology, Inc. | 2.2 Million USD | 577.57% |
| GB Sciences, Inc. | 1.74 Million USD | 701.837% |
| Alpha Cognition Inc. | -183.78 Thousand USD | -5621.81% |
| HST Global, Inc. | 96.79 Thousand USD | 10964.422% |
| CSL Limited | 10.52 Billion USD | 100.1% |
| Halberd Corporation | 144.72 Thousand USD | 7366.395% |
| Enzolytics Inc. | 981.65 Thousand USD | 1171.251% |
| Resverlogix Corp. | 6.45 Million USD | 263.013% |
| Affymax, Inc. | -5.59 Million USD | -87.886% |
| SYBLEU INC | 473.71 Thousand USD | 2319.905% |
| Nuo Therapeutics, Inc. | -673.08 Thousand USD | -1462.349% |
| argenx SE | -2.02 Billion USD | 99.482% |
| MetaStat, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | 43.43 Million USD | 124.211% |
| Enzon Pharmaceuticals, Inc. | -47.01 Million USD | 77.631% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | 488.243% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -8.83 Million USD | -18.96% |
| AVAX Technologies, Inc. | -5.9 Million USD | -78.14% |
| Zenith Capital Corp. | 10.06 Thousand USD | 104591.256% |
| Genscript Biotech Corporation | -1.06 Billion USD | 99.009% |
| Ember Therapeutics, Inc. | 200.43 Thousand USD | 5346.667% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | 2.38 Million USD | 540.731% |
| WPD Pharmaceuticals Inc. | 164.5 Thousand USD | 6492.355% |
| American Oriental Bioengineering, Inc. | 60.54 Million USD | 117.369% |
| Provectus Biopharmaceuticals, Inc. | 1.99 Million USD | 625.96% |
| Adynxx, Inc. | - USD | Infinity% |
| Helix BioMedix, Inc. | -2.57 Million USD | -309.178% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | 3023.466% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | 20.27 Million USD | 151.864% |
| Cotinga Pharmaceuticals Inc. | -18.31 Thousand USD | -57308.014% |
| BioStem Technologies, Inc. | 4.47 Million USD | 335.151% |
| ONE Bio Corp. | 9.04 Million USD | 216.327% |
| Reve Technologies, Inc. | 201.25 Thousand USD | 5325.238% |
| Burzynski Research Institute, Inc. | -1310.00 USD | -802648.092% |
| Wesana Health Holdings Inc. | 206.21 Thousand USD | 5199.483% |
| Agentix Corp. | 37.63 Thousand USD | 28045.045% |
| LadRx Corporation | -2.03 Million USD | -416.384% |
| Cell Source, Inc. | 9.23 Million USD | 213.909% |
| ProtoKinetix, Incorporated | -20.4 Thousand USD | -51428.812% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 1755.628% |
| Regen BioPharma, Inc. | 635.16 Thousand USD | 1755.628% |
| NovAccess Global Inc. | 2.17 Million USD | 582.725% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | 248.721% |
| Itoco Inc. | 228.3 Thousand USD | 4706.119% |
| Rasna Therapeutics, Inc. | 135.98 Thousand USD | 7832.978% |
| Pathfinder Cell Therapy, Inc. | 4.95 Million USD | 312.144% |
| Kadimastem Ltd | -253.1 Thousand USD | -4054.847% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | 2716.903% |
| CytoDyn Inc. | 20.26 Million USD | 151.9% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -647.00 USD | -1625247.759% |
| Mobile Lads Corp. | 484.23 Thousand USD | 2271.686% |
| NanoSphere Health Sciences Inc. | -9268.34 USD | -113361.526% |
| Qrons Inc. | 351.42 Thousand USD | 3092.371% |
| Alseres Pharmaceuticals, Inc. | 7.7 Million USD | 236.465% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| Nascent Biotech, Inc. | -249.62 Thousand USD | -4112.803% |
| Rebus Holdings, Inc. | 305 Thousand USD | 3547.869% |
| ImmunoCellular Therapeutics, Ltd. | 4.45 Million USD | 335.942% |
| International Stem Cell Corporation | 2.59 Million USD | 506.023% |
| Bioxytran, Inc. | 1.89 Million USD | 653.79% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | 16949.054% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | 582.186% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | 3.43 Million USD | 406.232% |
| Adhera Therapeutics, Inc. | 8.55 Million USD | 222.951% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | 772.6 Thousand USD | 1461.106% |
| Innovation Pharmaceuticals Inc. | -1.25 Million USD | -741.28% |
| Neutra Corp. | 52.18 Thousand USD | 20250.612% |
| Windtree Therapeutics, Inc. | -2.48 Million USD | -322.499% |
| PureTech Health plc | -167.19 Million USD | 93.71% |
| Coeptis Therapeutics, Inc. | -244.9 Thousand USD | -4193.857% |
| IXICO plc | -4.44 Million USD | -136.602% |
| IntelGenx Technologies Corp. | 13.21 Million USD | 179.552% |
| Gelesis Holdings, Inc. | 54.85 Million USD | 119.172% |
| CSL Limited | 10.52 Billion USD | 100.1% |
| Cellectis S.A. | -43.81 Million USD | 76.001% |